Capital International Ltd. CA Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Capital International Ltd. CA trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 20.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,282 shares of the biopharmaceutical company's stock after selling 20,141 shares during the quarter. Capital International Ltd. CA owned about 0.06% of Alnylam Pharmaceuticals worth $18,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the business. Alpha DNA Investment Management LLC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $710,000. CANADA LIFE ASSURANCE Co boosted its stake in Alnylam Pharmaceuticals by 11.9% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 76,919 shares of the biopharmaceutical company's stock valued at $18,087,000 after purchasing an additional 8,206 shares during the last quarter. Marshall Wace LLP boosted its stake in Alnylam Pharmaceuticals by 496.6% during the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock valued at $89,100,000 after purchasing an additional 315,182 shares during the last quarter. NewEdge Advisors LLC increased its holdings in Alnylam Pharmaceuticals by 97,200.0% during the 4th quarter. NewEdge Advisors LLC now owns 973 shares of the biopharmaceutical company's stock worth $229,000 after purchasing an additional 972 shares in the last quarter. Finally, Jump Financial LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $3,564,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares of the company's stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,234 shares of company stock valued at $19,958,097. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded up $4.44 during midday trading on Wednesday, hitting $241.19. 320,945 shares of the company traded hands, compared to its average volume of 872,182. The stock has a 50-day moving average of $247.91 and a 200-day moving average of $256.50. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm has a market cap of $31.38 billion, a P/E ratio of -111.15 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ALNY. Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research note on Friday, March 21st. Citigroup boosted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. StockNews.com raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $315.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.